Initiation of Phase I Trials for Photobiomodulation Therapy Signals Step Forward in Cancer and Inflammation Treatment
PILLAR DIAGNOSTIC // WEEK 50
“Given the uniform support from preclinical models showing consistent efficacy of photobiomodulation therapy across multiple disease contexts, we project a low-risk pathway toward translational studies. With no substantive inter-pillar conflicts, the therapy’s mechanism of immune modulation, microbiota diversification, and targeted cell death appears robust and reproducible, supporting progression to early-phase human trials.”
Proposed action
Proceed to design and initiate Phase I clinical trials focused on safety, tolerability, and biomarker validation. Standardize light dosimetry and treatment protocols, incorporate immune and microbiome monitoring, and engage regulatory bodies for streamlined approval.
THE MECHANICS
Spread & delivery
—
THE MACHINE
Evidence & systems
Photobiomodulation therapy consistently enhances treatment efficacy in colitis, cancer models, wound healing, addiction, and TMD by modulating immune responses, gut microbiota diversity, and inducing targeted cell death.
THE MAP
Policy & population
—
THE MOOD
Trust & behavior
—